Niusule Bio-Pharmace (OTC:NIUS)

It has been passed by company’s 2009 annual shareholders’ meeting to repurchase the common stock of the company sold from March 15-31, 2010 at USD0.5 per

Specific repurchase procedures are as follows:

1. Repurchase object: personal common shares (outstanding shares) of Niusule Biotech Corp.

2. Repurchase price: the repurchase price is USD0.5 per share

3. Period of repurchase: Oct.1.2010-Oct.31.2010

Based on current trends and planned expansion of its retail distribution network, Niusule management is now forecasting that revenue for CY 2010 is expected to be approximately $10 million. The Company estimates gross margin to be in the range of 70%-75% with net income of $2.5 to $3.0 million for CY 2010. The Company's current guidance is subject to financing.

Source: PR Newswire (November 18, 2009)